Table 1.

Comparison of PET tracers in prostate cancer

PET Agent	Advantages	Disadvantages	Comments
11C or 18F Choline	Min urinary excretion Availability	Lower sensitivity Non specific uptake	11C Choi ine approved by US FDA
18F FACBC	Improved sensitivity Local recurrence	Lower sensitivity Non specific uptake	18FACBC is approved by US FDA (Axumin)
68Ga or 18F PSMA	High sensitivity High specificity	False positive uptake	Soon to be available in US, Current gold standard
18F DHT	Reports AR activity	Difficult synthesis Noisy scans	Not commercially available
68Ga or 18F Bombesin	High sensitivity	False positive uptake	Not commercially available
18F FDG	Prognostic indicator Widely available	Insensitive in early dz.	18F FDG is approved by US FDA